Effect of an L- and T-type calcium channel blocker on 24-hour systolic blood pressure and heart rate in hypertensive patients
- PMID: 22563335
- PMCID: PMC3341419
- DOI: 10.4070/kcj.2012.42.4.231
Effect of an L- and T-type calcium channel blocker on 24-hour systolic blood pressure and heart rate in hypertensive patients
Abstract
Background and objectives: The aim of this study was to evaluate the effects of an L- and T-type calcium channel blocker (CCB) on 24-hour systolic blood pressure (24-hour SBP) and heart rate (24-hour HR) profiles in essential hypertensive patients.
Subjects and methods: Thirty-seven consecutive patients were enrolled in this study. The 24-hour SBP and HR were recorded before and after treatment with efonidipine (L- and T-type CCB, 40 mg), after waking. Changes in 24-hour SBP and HR and the diurnal to nocturnal SBP ratio were measured. The best-fit curves of changes in SBP and HR were depicted using a periodic function.
Results: The mean 24-hour SBP and HR decreased significantly after treatment. The diurnal to nocturnal SBP ratio in dipper-type hypertension cases decreased from 16.7±6.1% to 8.3±9.8% (p<0.05), whereas in non-dipper hypertension cases, it increased from 2.3±2.9% to 7.7±5.1% (p<0.01). The antihypertensive effect was minimal at 5.0 hours after drug administration and it slowly recovered at a constant rate (2.1 mm Hg/h) over 12 hours in dipper cases. The median 24-hour changes in HR in the dipper and non-dipper cases were -2.3/min and -5.4/min, respectively. A continuous reduction in the change in HR was seen from 3.5 to 23 hours after drug administration.
Conclusion: The antihypertensive action of efonidipine was characterized by a slow recovery of the SBP decrease at a constant rate (2.1 mm Hg/h) and a non-administration time dependent reduction in 24-hour HR.
Keywords: Blood pressure; Calcium channel blockers; Heart rate; Hypertension.
Conflict of interest statement
The authors have no financial conflicts of interest.
Figures







Similar articles
-
Effects of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, open-label pilot study.Curr Ther Res Clin Exp. 2003 Nov;64(9):707-14. doi: 10.1016/j.curtheres.2003.11.004. Curr Ther Res Clin Exp. 2003. PMID: 24944418 Free PMC article.
-
Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.Clin Ther. 2010 May;32(5):861-81. doi: 10.1016/j.clinthera.2010.04.020. Clin Ther. 2010. PMID: 20685495 Clinical Trial.
-
Beneficial Effect of Efonidipine, an L- and T-Type Dual Calcium Channel Blocker, on Heart Rate and Blood Pressure in Patients With Mild-to-Moderate Essential Hypertension.Korean Circ J. 2010 Oct;40(10):514-9. doi: 10.4070/kcj.2010.40.10.514. Epub 2010 Oct 31. Korean Circ J. 2010. PMID: 21088755 Free PMC article.
-
Prognostic Effect of the Nocturnal Blood Pressure Fall in Hypertensive Patients: The Ambulatory Blood Pressure Collaboration in Patients With Hypertension (ABC-H) Meta-Analysis.Hypertension. 2016 Apr;67(4):693-700. doi: 10.1161/HYPERTENSIONAHA.115.06981. Epub 2016 Feb 22. Hypertension. 2016. PMID: 26902495 Review.
-
The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target.Vasc Health Risk Manag. 2008;4(6):1315-25. doi: 10.2147/vhrm.s4073. Vasc Health Risk Manag. 2008. PMID: 19337545 Free PMC article. Review.
Cited by
-
Efonidipine, another beauty relieving the pressure.Korean Circ J. 2012 Apr;42(4):229-30. doi: 10.4070/kcj.2012.42.4.229. Epub 2012 Apr 26. Korean Circ J. 2012. PMID: 22563334 Free PMC article. No abstract available.
References
-
- Mancia G, de Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens. 2007;25:1105–1187. - PubMed
-
- Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res. 2007;100:342–353. - PubMed
-
- Masumiya H, Shijuku T, Tanaka H, Shigenobu K. Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect. Eur J Pharmacol. 1998;349:351–357. - PubMed
-
- Ge W, Ren J. Combined L-/T-type calcium channel blockers: ready for prime time. Hypertension. 2009;53:592–594. - PubMed
-
- Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev. 2003;83:117–161. - PubMed
LinkOut - more resources
Full Text Sources